Press Release

03rd November, 2026 The General Manager-Department of The Manager-Listing Department, Corporate Services, National Stock Exchange of India Limited, BSE Limited, "Exchange Plaza", 5th Floor, Phiroze Jeejeebhoy Towers, Plot No. C/1, G Block, Bandra-Kurla Complex, Dalal Street, Mumbai - 400 001. Bandra (East), Mumbai – 400 051. Scrip Code : 530999 Symbol : BALAMINES Dear Sir/Madam, Sub.: Press Release in connection with Un-audited Financial Results for the Quarter and Half Year ended 30th September, 2026 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please enclosed herewith a copy of Press Release in connection with the Un-audited Financial Results for the Quarter and Half Year ended 30th September, 2026. The aforesaid information is also being made available on the website of the Company at https://www.balajiamines.com/investor-relations.php. This is for your information and records. Thanking you. Yours faithfully, For Balaji Amines Limited Abhijeet Kothadiya Company Secretary & Compliance Officer Encl.: a/a Investor Release For Immediate Release Consolidated Q2 FY27 Revenue stood at ₹ 472 Crore; EBITDA stood at ₹ 106 Crore; Net Profit stood at ₹ 67 Crore Solapur, 2nd November 2026: Balaji Amines Limited (“Company”), a leading manufacturer of Aliphatic Amines & Speciality Chemicals in India, specialised in manufacturing of Methyl Amines, Ethyl Amines, Derivatives of Amines and other Speciality Chemicals, announced its unaudited financial results for the quarter and half year ended September 30th, 2026. Key Financial Highlights are as follows: Particulars (₹ Cr.) Standalone Consolidated Q2FY27 Q2FY26 H1FY27 H1FY26 Q2FY27 Q2FY26 H1FY27 H1FY26 Total Revenue (Rs. Cr) 434 316 863 643 472 348 933 715 EBITDA (Rs. Cr) 103 57 213 121 106 67 227 131 EBITDA Margin (%) 24% 18% 25% 19% 22% 19% 24% 18% PAT (Rs. Cr) 69 31 141 71 67 37 146 74 PAT Margin (%) 16% 10% 16% 11% 14% 11% 16% 10% Cash PAT* (Rs. Cr) 84 48 173 101 86 57 183 109 Cash PAT Margin (%) 19% 15% 20% 16% 18% 16% 20% 15% Sales Volume (in MT) 22,917 24,524 43,536 49,371 24,491 26,165 46,078 53,735 *Cash PAT is PAT + Depreciation + Deferred tax Consolidated Performance Highlights for Q2 FY27 Total Revenue for Q2FY27 stood at ₹ 472 crore, as compared to ₹ 348 crore in Q2FY26, indicating stable operational performance. Volumes were maintained at similar levels, supported by stable commodity prices and consistent demand across key segments. Total volumes stood at 24,491 MT for Q2FY27 as against 26,165 MT in Q2FY26. For Q2FY27, ● Amines volumes stood at 6,525 MT ● Amines Derivatives volumes stood at 8,974 MT ● Specialty Chemicals volumes stood at 8,992 MT EBITDA for Q2 FY27 was ₹ 106 crore, as compared to ₹ 121 crore in Q1FY27 and ₹ 67 crore in Q2FY26. EBITDA margin for Q2FY27 stood at 22% as against 26% in Q1FY27 and 19% in Q2FY26. PAT for Q2FY27 was ₹ 67 crore as compared to ₹ 37 crore in Q2FY26. Diluted EPS for Q2FY27 stood at ₹ 20.76 per equity share as against ₹ 10.67 in Q2FY26. On a standalone basis, we are a zero-debt company. Growth Drivers & Expansion Pipeline The Company continues to strengthen its growth platform through capacity expansion, import substitution opportunities, and a sharper focus on value-added specialty chemicals. During the period, commercial production commenced at the expanded Acetonitrile (ACN) facility, increasing installed capacity to 1,440 TPM. The upgraded plant incorporates advanced technology and enhanced process efficiencies, positioning the Company to improve operational performance over the medium term. Following the successful commissioning of its 100,000 TPA Dimethyl Ether (DME) plant, India's first commercial-scale DME facility, the Company has established a presence in a high-potential import substitution market with applications spanning healthcare, personal care products as Aerosol application apart from usage as a fuel for various applications. Further, the DME Road Tanker valves are finally approved after a rigorous testing process of PESO. The next phase of work is in the pipeline to establish a robust network of customers as the company has already studied the ever expanding Aerosol market. There are opportunities for export of DME which are explored on a regular basis. The next product planned for commercialization is N-Methyl Morpholine (NMM), further expanding the specialty chemicals portfolio. In parallel, Balaji Speciality Chemicals is progressing with its expansion program that is aimed at increasing the share of high-value specialty chemicals. The Unit-I brownfield expansion, comprising EDA derivatives such as DETA, TETA, Piperazine, AEEA, and AEP, remains on track for commissioning during the end of FY27. The Unit-II greenfield project at MIDC, Chincholi, which will manufacture HCN, NaCN, EDTA, and EDTA-2Na, is targeted for commissioning in Q4 FY27. These investments are expected to broaden the product portfolio, enhance backward integration, increase exposure to higher-margin specialty chemicals, and create a strong foundation for the Company's next phase of growth. On the performance, Mr. D. Ram Reddy, Managing Director, commented, Q2 FY27 reflected resilient execution and steady progress on our strategic priorities. As we enter H2 FY27, our focus is firmly on driving higher utilization, improving operating efficiencies and translating recent investments into stronger earnings growth. The commissioning of the upgraded Acetonitrile (ACN) facility and the DME plant marks an important step in expanding our presence in value-added and import-substitution products. We are now focused on scaling these capacities and unlocking their full commercial potential. We have also improved the process of Di Isopropylamine (DIPA) as continuous efforts yielded this success. Overall, the volumes have dented due to various external factors, however the company has leveraged its strength in stabilising the product portfolio to keep the top line stable and continuing the efforts to strengthen the bottom line. Our growth pipeline remains robust, with N-Methyl Morpholine (NMM) and multiple specialty chemical projects progressing as planned. These investments will further strengthen our specialty chemicals portfolio, enhance integration and expand our participation in high-growth end markets. With a stronger product mix, a visible expansion roadmap and a disciplined focus on execution, we remain confident in our ability to drive sustainable growth, improve earnings quality and create long-term value for shareholders. About Balaji Amines Limited (BAL) Balaji Amines Ltd (BAL), set up in 1988, is a leading manufacturer of Aliphatic Amines in India. Broadly, the company is specialised in manufacturing Methyl Amines, Ethyl Amines, Derivatives of Aliphatic Amines and Specialty Chemicals. Its business is broadly classified into three segments - Amines, Specialty Chemicals and Derivatives. BAL commenced manufacturing of Methyl Amines in 1990 and later added facilities of Ethyl Amines and other derivatives of Methyl Amines and Ethyl Amines. The company enjoys leadership position in many of its products like Monomethylamine (MMA), Dimethyl amine (DMA), Trimethylamine (TMA), Dimethyl Amino Ethanol (DMAE), Mono Methyl Amino Ethanol etc. It caters to a host of industries like Pharma, Agro Chemicals, Paint Stripping & Resins, Rubber cleaning chemicals etc. The company has four state of the art manufacturing sites – three near Solapur and one near Hyderabad. In addition, BAL possesses a fully furnished Laboratory which helps the company in development of newer products. A majority of its products are being exported to major customers worldwide and the company has become one of the leaders in Specialty Chemicals among the International Specialty Chemical players. The company also operates a 5-star hotel in Solapur – Balaji Sarovar. It has tied up with Sarovar group for management of this hotel. For more information, please visit [Showing first 8,000 characters — download PDF for full document]